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The role of the hepatitis B virus X protein (HBx) in the pathogenesis
of hepatitis B virus (HBV) infection remains unclear. HBx exhibits
pleiotropic biological effects, whose in vivo relevance is a matter
for debate. In the present report, we have used a combination of
HBx-expressing transgenic mice and liver cell transplantation to
investigate the in vivo impact of HBx expression on liver cell
proliferation and viability in a regenerative context. We show that
moderate HBx expression inhibits liver regeneration after partial
hepatectomy in HBx-expressing transgenic mice. We also demon-
strate that the transplantation of HBx-expressing liver cells, iso-
lated from HBx transgenic mice, is sufficient to inhibit overall
recipient liver regeneration after partial hepatectomy. Moreover,
the injection of serum samples drawn from HBx-expressing trans-
genic mice mimicked the inhibitory effect of HBx on liver regen-
eration. Finally, the incubation of primary rat hepatocytes with the
supernatant of HBx-expressing liver cells inhibits cellular DNA
synthesis. Taken together, our results demonstrate a paracrine
inhibitory effect of HBx on liver cell proliferation and lead us to
propose HBV as one of the few viruses implicated in human cancer
which act, at least in part, through paracrine biological pathways.
Hepatitis B virus (HBV) is a major pathogen that chronicallyinfects more than 300 million individuals worldwide. Chronic
HBV infection is an important cause of death through induction of
cirrhosis and hepatocellular carcinoma (HCC) (1–3). Liver inflam-
mation triggered by the host immune response to the virus is a
major factor contributing to the development of HCC; it induces
fibrosis and liver cell proliferation and, eventually, deregulated liver
cell expansion (4, 5). There is also evidence that HBV has a direct
impact on the cellular machinery. Integration of the viral genome
into the host genome can induce chromosomal instability; it may
also integrate in the vicinity of genes controlling cell proliferation,
viability, and differentiation. Our recent findings have shown that,
in contrast with previously held views, this mechanism may in fact
be prevalent (1, 6, 7).
In addition, a number of studies have shown the capacity of
certain HBV proteins, namely HBVx protein (HBx) (8–10), trun-
cated envelope PreS2St (11), and a splice-generated protein
(HBSP) (12), to modulate cell proliferation and viability. HBx has,
in particular, been the focus of several investigations. This protein
is expressed at all stages of viral infection and has been implicated
in the establishment of viral infection in woodchucks infected by the
woodchuck hepatitis virus (WHV), an HBV-related virus from the
Hepadna virus family (13). In most in vitro and in vivo studies, HBx
has exhibited no, or only a very weak, oncogenic effect, although
HBx has been shown to induce HCC in certain lines of transgenic
mice (14) and may cooperate in vitro, under some conditions, with
activated ras oncogene (15). Taken together, these observations and
the overall results obtained in various HBx-expressing transgenic
mice with different genetic backgrounds have led to the suggestion
that HBx may act as a promoting agent during liver carcinogenesis,
in particular, by cooperating with the c-myc oncogene and by
sensitizing liver cells to carcinogenic chemicals (16, 17).
HBx exhibits a predominantly cytoplasmic localization (partly
associated with the proteasome and mitochondria) although, at
least under some experimental conditions, nuclear HBx can be also
detected (18–20). In vitro, it has been well established that HBx
transactivates a variety of cellular gene promoters by acting on
several cis-acting elements such as NF-B, AP1 and AP2, and CRE
(8, 10). HBx does not bind DNA. It activates signal-transduction
cascades such as the RasRaf mitogen-activated protein kinase,
c-Jun NH2-terminal kinase, JAKSTAT, and, possibly, protein
kinase C (21–24). HBx may also directly interact with transcription
factors, such as cAMP response element binding proteinactivating
transcription factor (CREBATF) (8), and with regulatory mole-
cules, such as IB (25), it may also affect basal transcriptional
regulation by binding RNA polymerase II subunit 5 (26), transcrip-
tion factor IIB (27, 28), TATA-binding proteins, and transcription
factor II (26, 29). In addition, HBx may also directly bind a number
of important cellular regulatory molecules controlling cell viability
and proliferation, such as p53 (30), UVDD (31), ERCC3 DNA
repair (32), nuclear export CRM1 (33), and senescence-related
factor (34).
Depending on the experimental conditions, discrepant results
have been shown regarding the effects of HBx ectopic expression on
cell proliferation and apoptosis. In fact, HBx has been reported to
block p53- (35), Fas-, tumor necrosis factor  (TNF)- (36),
transforming growth factor  (TGF)- (37) dependent apoptosis as
well as caspase 3 activity (38); in most recent reports, however, HBx
has been shown to induce or sensitize to apoptosis, by using
p53-dependent and independent mechanisms (39–44). HBx-
dependent apoptosis can be suppressed by activating the phospha-
tidylinositol 3 kinaseAkt (45), insulin-like growth factor II (43),
and bcl2 pathways (42, 46). The level of HBx expression achieved
in experiments based mainly on transient expression and the cell
type investigated is an important factor influencing the overall
cellular effects of HBx; the importance of the intracellular level of
HBx has been well illustrated in in vivo experiments with HBx-
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expressing transgenic mice (16, 41, 47, 48). In addition, our group
and others have recently shown that mutations identified in HBx-
encoding sequences in the tumor cells of HCC patients can mark-
edly modify the biological activity of HBx and abrogate its proapo-
ptotic effects. Our results have led us to suggest a model, whereby
mutations in HBx sequences may favor the selection and, thus, the
clonal expansion of certain HBV-infected liver cells in chronically
infected HBV carriers (9, 44, 49).
As mentioned above, studies based on the in vitro ectopic
expression of HBx produced variable results that reflect the dif-
ferent in vitro experimental protocols used. Extracellular signals
may also significantly affect the differentiation status of a cell and
its response to HBx expression; in this respect, in vivo studies in
HBx-expressing transgenic mice have provided important informa-
tion but their results have also shown discrepancies, due in partic-
ular to the different genetic backgrounds of the mice used and the
different levels of HBx accumulation (14, 16, 50). In addition, the
expression of HBx in most transgenic mouse liver cells does not fully
mimic the situation observed in infected patients. Indeed, HBx is
expressed in a small proportion of liver cells in patients with chronic
hepatitis and cirrhosis and in the tumor cells of patients with HCC
(19, 49, 51). Moreover, a major feature of the pathogenesis of HBV
infection is the expression of viral proteins in the context of
inflammation and liver cell regeneration (4).
In the present study, we wished to address the major issue of the
in vivo effects of HBx on cell proliferation and viability in the
context of a regenerative signal. Therefore, using HBx-expressing
transgenic mice, we first investigated whether HBx expression
affected the potential for liver regeneration after partial hepatec-
tomy. We took advantage of the interesting characteristics of the
AX16, HBx-expressing, transgenic line (16, 52), that expresses a
moderate amount of HBx soon after birth, the levels declining as
the animals become older. Furthermore, we benefited from recent
advances in liver cell transplantation, which may offer new exper-
imental approaches to address these issues (53–55). We reasoned
that the transplantation of HBx-expressing hepatocytes isolated
from HBx-expressing transgenic mice into nontransgenic mouse
liver, and the induction of liver regeneration by partial hepatectomy
would indeed allow us to investigate the effects of HBx expression
in the context of a low percentage of HBx-expressing liver cells
undergoing in vivo proliferation. Using this approach, we demon-
strate a paracrine action of HBx and propose a model for HBx-
dependent pathogenesis.
Materials and Methods
Animals. AX16 transgenic mice carry the HBx ORF linked to the
promoter-enhancer of the human antithrombin III gene and have
been described in detail elsewhere (52). The HNF1-LacZ trans-
genic mice carry the nls-LacZ gene driven by the regulatory region
of the hepatocyte nuclear factor 1 (HNF-1) rat gene. The transgene
contains 3.3 kb of the HNF-1 promoter (56) linked to the nls-LacZ
gene containing the simian virus 40 early region polyadenylation
signal (57) (gift from M. Pontoglio and M. Yaniv, Pasteur Institute,
Paris). AX16HNF1-LacZ double-transgenic mice were generated
by crossing homozygous AX16 and HNF1-LacZ mice, derived from
the same parental strain of inbred mice. The experiments were then
carried out on these AX16HNF1-LacZ double-transgenic mice
(referred to as HBx-LacZ) and using HNF1-LacZ transgenic mice
(referred to as LacZ) as controls. Previous studies have docu-
mented, by using Western Blot analysis, a moderate expression of
the HBx protein in 10-day-old animals and a lack of detection of
HBx at later time points (90-day-old mice) (16).
Six-week-old female severe combined immunodeficient (SCID)
mice (IFFRA-CREDO, Lyon, France) were used as the recipients
of hepatocytes isolated from HBx-LacZ and LacZ transgenic mice,
to minimize any risk of cell rejection.
Liver Cell Isolation, Transplantation, and Partial Hepatectomy. Hepa-
tocytes were isolated from 10-, 15-, and 90-day-old HBx-LacZ
and LacZ mice by using collagenase (Collagenase Hepatocyte
Qualified—GIBCOBRL), as described (58). SCID mice were
anesthetized with xylazine (Bayer, Leverkusen, Germany) and
ketamine (Rhoˆne Me´rieux, Lyon, France) dissolved in PBS, spleens
were exteriorized through a small, left-flank incision, and a syringe
with a 26-gauge needle was used to inject 100 l of cell suspension
(5  105 to 1  106 viable hepatocytes) in Williams medium
(GIBCOBRL). Recipient SCID mice were held for 30 days to
allow sufficient time for the proliferation and reorganization of
donor hepatocytes into the liver parenchyma, before partial hep-
atectomy was performed. During this procedure, the left lobe and
part of the median lobe of the liver were removed through a
mid-abdominal incision (59). All animals were killed 8 days after
partial hepatectomy.
Serum Injection After Partial Hepatectomy. Serum was obtain-
ed from 10-, 15-, and 90-day-old HBx-LacZ mice, and 100 l
serum was injected into the spleens of SCID mice 1 day after
partial hepatectomy. The animals were killed 8 days after partial
hepatectomy.
Detection of Transplanted Liver Cells. PCR analysis. Genomic DNA
was extracted from frozen liver tissues by proteinase K digestion,
phenol extraction, and ethanol precipitation. LacZ genomic se-
quences were detected in transplanted SCID mice livers by PCR
using specific LacZ primers (sense 5-TCACACTACGTCT-
GAACGTCG-3; and antisense 5-CTGCTTCATCAGCAG-
GATATCC-3). PCR was performed with 30 amplification cycles
of 30 s each at the following temperatures: 94°C, 57°C, and 72°C.
Murine genomic DNA was detected by amplifying the murine
c-mos protooncogene as described (60).
Hepatocyte DNA staining using Hoechst fluorochrome. After
isolation, viable hepatocytes were resuspended in 2 ml of Williams
medium (GIBCOBRL), and incubated for 30 min at 37°C with 3
l of Hoechst 33258 (10 mgml) (Sigma). After the inhibition of
Hoechst fluorochrome with 2 ml of fetal calf serum (FCS), the cell
suspensions were centrifuged three times at 50 g, resuspended in
Williams medium (GIBCOBRL) and 10% FCS, and then trans-
planted into recipient SCID mice by intrasplenic injection. Eight
days after transplantation, liver samples were obtained by partial
hepatectomy, frozen sections were cut (7 m) with a cryostat, and
Hoechst labeling was visualized under a fluorescence microscope.
Three independent fields were analyzed.
In vivo detection of LacZ expression. LacZ expression was tested
on 4% paraformaldehyde-fixed, paraffin-embedded liver sections
(5 m) obtained during and 8 days after partial hepatectomy
by using anti-LacZ antibodies (Rockland, Gilbertsville, PA), as
described (61).
Evaluation of Liver Regeneration. Overall liver regeneration was
evaluated by weighing the mice and remaining livers after eutha-
nasia, and by analyzing DNA synthesis by using 5-bromo-2-
deoxyuridine (BrdUrd) incorporation as described (16). BrdUrd
(Sigma) was injected i.p. 24 h and 36 h after partial hepatectomy at
a rate of 0.1 mgg of body weight. The animals were killed 48 h after
partial hepatectomy. Three independent fields were counted.
In Situ Detection of Apoptosis After Partial Hepatectomy. The pres-
ence of apoptosis was sought in SCID mice transplanted with
HBx-LacZ and LacZ hepatocytes. The liver cells of SCID mice
undergoing apoptosis were labeled by using in situ nick end labeling
of nucleosomal DNA (TUNEL), as described (16). Apoptotic
hepatocytes were quantified by counting five consecutive optical
fields.
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RNase Protection Assay (RPA). Total RNA was extracted from livers
by using RNAble (Eurobio, Paris), following manufacturer’s in-
structions. [-32P]UTP-labeled antisense RNA transcripts pre-
pared from mCK3 DNA template (Riboquant, PharMingen), using
a MAXIscript in vitro transcription kit (Ambion, Austin, TX), were
hybridized with 20 g of total RNA overnight at 56°C, as per
manufacturer’s instructions. Bands were detected by phosphoim-
aging using IMAGE QUANT software (Molecular Dynamics). Results
were calculated as a ratio of the volume of the band of interest to
the mean of the volumes of the bands for the housekeeping genes
encoding the large ribosomal protein L32 and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH).
Effect of HBx-Conditioned Medium on DNA Synthesis in Primary Rat
Hepatocytes. HuH7 human hepatoma cells were transfected with 20
g of the HBx Myc-tagged-expressing plasmid, or empty vector, by
using the calcium phosphate precipitation technique. Sixteen hours
after transfection, the cells were washed and fresh medium was
added. Conditioned medium was harvested 48 h posttransfection.
Transient expression of HBx protein was confirmed by Western blot
analysis (9). Primary hepatocytes were isolated from 5-week-old
male Wistar rats and cultured, as described (62). After plating,
conditioned media were added. In some experiments HBx- and
neo-expressing HuH7 cell supernatants were first incubated either
with 10 gml of rabbit anti-HBx antiserum (kind gift of P.
Arbuthnot, University of Witwatersrand, Parktown, South Africa),
or with 2 gml monoclonal anti-Myc antibody (Santa Cruz
Biotechnology) for 2 h and then pulled down with protein G-
Sepharose beads (Amersham Pharmacia Biotech) before being
added to primary rat hepatocytes. BrdUrd was added 12 h before
cell fixation in accordance with the manufacturer’s instructions
(Roche Molecular Biochemical). The percentage of cells undergo-
ing DNA synthesis was estimated by counting the number of
BrdUrd-labeled cells.
Statistical Analysis. The data are presented as means  standard
deviations (SD). Statistical analysis was performed by using a
nonparametric Student’s t test (P  0.05).
Results
The aim of the study was to assess the effect of HBx expression
on liver cell proliferation in vivo in the context of liver regen-
eration after partial hepatectomy. Experiments were carried out
in both HBx-LacZ and LacZ transgenic mice, as well as in SCID
mice transplanted with hepatocytes isolated from these trans-
genic mice. We took advantage of the LacZ transgene present in
transgenic mice to monitor the fate of transplanted liver cells.
This LacZ sequence was also used as an internal control of the
biological effects of HBx, because we could comparatively
investigate hepatocytes derived from HBx-LacZ and LacZ trans-
genic mice.
In HBx-LacZ transgenic animals, we first determined whether
the expression of HBx might modify the degree of liver regenera-
tion after partial hepatectomy. Experiments were performed at two
time points (30 and 90 days after birth) in HBx-LacZ mice to
evaluate the impact of moderate (30-day-old animals) or absent
(90-day-old animals) HBx expression on the results. At each time
point, we compared the weight of the remaining liver 8 days after
partial hepatectomy in HBx-LacZ and LacZ transgenic mice.
Partial hepatectomy performed in 30-day-old animals induced a
23% reduction in mouse liver weight in HBx-LacZ transgenic
animals (0.86  0.12 g) when compared with LacZ mice (1.11 
0.19 g) (P  0.01). In contrast, no significant difference
was observed in liver weight in HBx-LacZ (1.19  0.12 g) and
LacZ (1.06  0.25 g) animals when partial hepatectomy was
performed at 90 days after birth (Fig. 1). This result shows that the
expression of HBx inhibited overall liver regeneration after partial
hepatectomy.
We then set up an in vivo experimental model to test for the effect
on overall liver regeneration of HBx expression in a minority of liver
cells. We thus performed liver cell transplantation of hepatocytes
isolated from HBx-LacZ and LacZ transgenic mice, and then tested
in the SCID recipient mice the extent of liver regeneration after
partial hepatectomy. Two complementary approaches were used to
assess liver cell transplantation. First, we visualized transplanted
liver cells by using Hoechst staining. As shown in Fig. 2a, Hoechst-
positive cells were detected in the liver of recipient mice 8 days after
intra-splenic transplantation in the absence of partial hepatectomy.
A semiquantitative estimation indicated that transplanted cells
constituted less than 11000 in the recipient livers. Second, we took
advantage of the presence of the LacZ sequence in both the
HBx-LacZ and LacZ transgenic mouse liver cells used for trans-
plantation to perform PCR analysis. As shown in Fig. 2b, LacZ
sequences were indeed detected by PCR in recipient SCID liver
after partial hepatectomy, thus confirming liver cell transplantation.
Moreover, LacZ expression was shown in a limited number of liver
cells (fewer than 11000) without preferential distribution in the
liver sections obtained 8 days after partial hepatectomy (Fig. 2c).
These results demonstrated that transplanted cells persisted upon
stimulation of recipient liver regeneration and retained their trans-
gene expression.
We then assessed the effects of the intrahepatic implantation of
liver cells concerning the extent of liver regeneration after partial
hepatectomy. Macroscopic evaluation of the liver 8 days after
partial hepatectomy showed a marked reduction in liver mass in 8
of 10 recipient mice transplanted with liver cells from 10- to
15-day-old HBx-LacZ mice, compared with 2 of 11 mice trans-
planted with 10- to 15-day-old LacZ mouse liver cells (see repre-
sentative results in Fig. 3A). In contrast, no macroscopic modifi-
cation was observed when mice transplanted with 90-day-old HBx-
LacZ or LacZ hepatocytes were compared. These findings,
although clearly reproducible, were not confirmed by liver weight
measurements (Fig. 3B). However, BrdUrd incorporation analysis
performed 48 h after partial hepatectomy did confirm a marked
reduction (5.5-fold) in cellular DNA synthesis after the transplan-
tation of HBx-expressing hepatocytes isolated from 10- to 15-day-
old transgenic mice (P 0.002) (Fig. 4C). Thus, the transplantation
of around 106 hepatocytes was sufficient to inhibit liver regenera-
tion after partial hepatectomy. Standard histological examination of
the liver did not reveal any obvious morphological changes (data
not shown). Thus, to determine whether increased liver cell apo-
Fig. 1. Inhibition of liver regeneration after partial hepatectomy in HBx-LacZ
transgenic mice. Box plots of the liver weights of transgenic mice 8 days after
partial hepatectomy. Partial hepatectomy was performed on HBx-LacZ or LacZ
transgenic mice at days 30 or 90 after birth, as described in Materials and
Methods. Each box has its ends at the quartiles, and the median of distribution is
marked by a line within the box. n corresponds to the number of animals in each
group.
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ptosis might contribute to the inhibition of liver regeneration, we
performed a terminal deoxynucleotide transferase-mediated dUTP
end labeling (TUNEL) assay. There was no apparent increase in the
percentage of apoptotic liver cells 1, 2, or 8 days after partial
hepatectomy in mice transplanted with HBx-LacZ hepatocytes
(data not shown). Therefore, the reduction in cellular DNA syn-
thesis mostly accounted for the inhibition of liver regeneration.
This inhibition of overall liver regeneration with the expression
of HBx in only a small proportion of liver cells strongly suggests that
HBx acted on both HBx-expressing cells and HBx-negative liver
cells. To investigate this further, we tested whether the injection of
serum from HBx-expressing transgenic mice might have the same
effect as transplantation on liver regeneration. We therefore com-
pared the weights of remnant livers 8 days after partial hepatectomy
in SCID mice that had been injected at day 1 after partial hepa-
tectomy with 100 l of serum obtained from HBx-LacZ 10- to 15-
and 90-day-old mice. Fig. 3B shows a 17% lowering of liver weight
in mice injected with serum from 10- to 15-day-old HBx-LacZ
(0.88  0.11 g), compared with that seen in HBx-LacZ 90-day-old
transgenic mice (1.05  0.14 g) (P  0.02). This observation was
consistent with HBx triggering the secretion in serum of a factor
Fig. 2. Detection of transplanted hepatocytes in recipient liver. (a) Hoechst
33258-positive cells were detected in frozen liver sections from SCID recipient
mice 8 days after intrasplenic transplantation. (Magnification, 100.) In the
upper left corner is a400 magnification of the selected area. (b) PCR analysis for
LacZ gene or murine-specific c-mos protooncogene. Genomic DNA was extracted
from the liver of SCID mouse (lane 1) and from the liver of donor HNF1-LacZ
transgenic mice (lane 2). The LacZ sequence was detected in genomic DNA from
transplanted SCID liver with LacZ hepatocytes (lanes 3 and 4) and HBx-LacZ
hepatocytes (lanes 5 and 6). (c) In vivo detection of LacZ expression by immuno-
histochemical staining. (Upper Left) HBx-LacZ donor mouse liver (positive con-
trol). (Upper Right) Untransplanted SCID mouse liver (negative control). (Lower
Left) SCID mouse liver transplanted with HBx-LacZ hepatocytes. (Lower Right)
SCID mouse liver transplanted with LacZ hepatocytes.
Fig. 3. Inhibition of liver regeneration in SCID mice transplanted with
hepatocytes or injected with serum from HBx-LacZ or LacZ transgenic mice. (A)
Macroscopic evaluation of the livers of SCID mice transplanted with hepato-
cytes from 10- to 15-day-old HBx-LacZ transgenic mice (HBx-LacZ 15d) or 10- to
15-day-old LacZ transgenic mice (LacZ 15d) 8 days after partial hepatectomy.
(B) Box plots of the liver weights of transplanted (hepatocytes) or injected
(serum) SCID mice after partial hepatectomy. Transplanted hepatocytes were
obtained from 10- to 15-day-old HBx-LacZ mice (HBx-LacZ 15d), or 10- to
15-day-old LacZ mice (LacZ 15d) or from 90-day-old HBx-LacZ mice (HBx-LacZ
90d) or 90-day-old LacZ mice (LacZ 90d). Serum was obtained from 10- to
15-day-old HBx-LacZ mice (HBx 15d) or 90-day-old HBx-LacZ mice (HBx 90d).
Fig. 4. Inhibition of liver regeneration by in vivo HBx expression. Immunohis-
tochemical detection of S-phase hepatocytes 48 h after partial hepatectomy by
BrdUrd incorporation in SCID mice transplanted with liver cells from 10- to
15-day-old HBx-LacZ transgenic mice (A) and SCID mice transplanted with liver
cells from 10- to 15-day-old LacZ transgenic mice (B). BrdUrd-positive nuclei were
stained in dark brown. (C) In situ S-phase index 48 h after partial hepatectomy in
SCID mice transplanted with 10- to 15-day-old HBx-LacZ liver cells and with 10- to
15-day-old LacZ liver cells.
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capable of inhibiting liver regeneration. Several cytokines have
been involved in liver regeneration control. We tested, therefore,
whether in vivo HBx expression, both in HBx-positive transgenic
mice and in mice transplanted with HBx-expressing liver cells,
might modify intrahepatic cytokine RNA expression. We did not
show any significant difference in TNF  and , interleukin-6
(IL-6), IFN  and , or TGF1 and -2 RNA expression (data not
shown).
To confirm in vitro that HBx may act by a paracrine effect, we
tested isolated primary rat hepatocytes on whether the in vitro
ectopic expression of HBx might induce secretion into the medium
of a soluble factor capable of mimicking our in vivo observation. Fig.
5 shows that the addition to primary rat hepatocytes of an HBx-
expressing HuH7 cell supernatant, and not a control supernatant,
induced a marked reduction in BrdUrd incorporation, 60 [3.2-fold
(P 0.003)], 72 [5.6-fold (P 0.001)], and 84 [20-fold (P 0.001)]
h after plating.
Given these results, we tested for a direct effect of HBx on
hepatocyte proliferation. Thus, we investigated the effect of HBx-
expressing cell supernatant previously incubated with polyclonal
anti-HBx antibodies on BrdUrd incorporation. However, we failed,
in our experimental conditions, to obtain conclusive results (data
not shown). Thus, as a complementary approach, we took advan-
tage of Myc-tag present in HBx-expressing sequence and tested
whether incubation of HBx-expressing cell supernatant with anti-
Myc antibodies would abrogate the inhibitory effect of the super-
natant on primary rat hepatocyte DNA synthesis. We failed,
however, to show such abrogation (data not shown).
Overall, the results of in vivo and in vitro experiments were
entirely consistent and showed a direct or indirect paracrine action
of HBx. Further studies are clearly needed to dissect the fine
mechanisms of such HBx-dependent effect, but the present data
point to the induction, upon HBx expression, of a protein acting on
adjacent liver cells.
Discussion
Taken together, our results demonstrate another mechanism for
the biological effects of HBx and lead us to propose HBV as one
of the few viruses implicated in human cancer that act, at least
in part, through paracrine biological pathways.
In HBx-expressing mice, either transgenic or transplanted with
HBx-expressing hepatocytes, we were able to demonstrate that HBx
could inhibit the in vivo liver regeneration triggered by partial
hepatectomy. We took advantage of the different levels of intra-
cellular HBx expression observed in the young and older transgenic
mice used for this study and showed that this effect was observed
only in the context of intracellular HBx accumulation. Further-
more, these results were obtained in the context of moderate HBx
expression. That HBx inhibits cell proliferation is consistent with
the results of several in vitro studies (39–46, 48, 63). Thus, the in vitro
ectopic expression of HBx can induce cell cycle arrest and liver cell
apoptosis and, in vivo, the detection of liver cell apoptosis could be
correlated, in the HBx-expressing transgenic mice utilized in our
study, with HBx accumulation, as observed in young, but not in
older, animals (16). In our present experimental model, the regen-
eration of whole recipient liver after partial hepatectomy was
markedly reduced, as assessed by morphological inspection and
liver weight measurements. BrdUrd incorporation and TUNEL
assays showed that this reduction in liver regeneration was mostly
because of a decrease in liver cell DNA synthesis, whereas we did
not detect any increase in liver cell apoptosis. This result suggests
that, at least under the in vivo stimulation of liver cell proliferation,
the principal overall effect of moderate HBx accumulation is cell
cycle arrest.
Strikingly, the results of our experiments performed to compare
the transplantation of hepatocytes and the injection of serum
samples from HBx-expressing transgenic mice established that
HBx-dependent biological effects could not be accounted for solely
by the intracellular effects of HBx, because the transplantation of
about 5 105 HBx-expressing hepatocytes was sufficient to reduce
liver regeneration. Importantly, this inhibitory effect was also
achieved by injecting serum samples from HBx-expressing mice.
Our in vitro experiments, demonstrating an inhibitory effect of
HBx-expressing cell supernatants on primary rat hepatocyte DNA
synthesis, provided additional arguments in favor of a paracrine
action for HBx. Indeed, the results obtained after partial hepatec-
tomy in HBx-expressing transgenic mice, in nontransgenic mice,
and in mice either transplanted with HBx-positive hepatocytes or
injected with serum from HBx-transgenic animals were entirely
consistent and led us to conclude that HBx would exert an inhib-
itory paracrine effect on liver regeneration.
A paracrine effect of viral proteins on cell transformation and
angiogenesis has been hypothesized for only a few human viruses
implicated in carcinogenesis. Thus, the Kaposi sarcoma-associated
herpes virus (KSHV or HHV8) acts in part through the stimulation
of uninfected endothelial cells, and particularly through the secre-
tion of vascular endothelial growth factor (VEGF) receptor 2 (64,
65), the HIV Tat (66) and HTLV-I Tax (67) proteins induce the
expression and secretion of cytokines that stimulate adjacent cell
proliferation and gene transactivation. It has also been suggested
that HHV8 may participate in myeloma by inducing IL6 secretion
(68, 69). In all these conditions, viral infection in a limited percent-
age of cells triggers the proliferation of adjacent cells through the
secretion of either a viral protein or growth factorscytokines. Our
results provide an alternative model whereby a viral protein may in
fact induce an inhibitory effect on the proliferation of uninfected
cells. The nature of the inhibitory signal triggered by HBx remains
unclear. Several cytokines and growth factors have been shown to
regulate liver cell proliferation in a positive fashion, although only
a few candidate molecules have so far been identified as inhibiting
liver regeneration. Of these, we investigated the potential implica-
tion of TGF, given its importance to the negative regulation of
liver regeneration after partial hepatectomy (53, 70), the frequent
deregulation of the TGF-related pathway in different models of
liver carcinogenesis, and the documented activation of TGF
expression by HBx (71). However, we found no evidence of any
increase in TGF intrahepatic mRNA expression and its secretion
in serum of HBx-transgenic mice or in culture media of HBx-
transfected cells (data not shown). On the other hand, it is plausible
that HBx itself may be secreted; anti-HBx antibodies can be
Fig. 5. Inhibition of cell proliferation by in vitro HBx expression. (A) BrdUrd
incorporation in cultured primary rat hepatocytes incubated for the indicated
times with the supernatant of HuH7 cells transfected with the HBx expression
vector (HBx) or control plasmid (HBx-). (B and C) Representative results of light
microscopy examination of primary rat hepatocytes incubated for 60 h with HBx-
(B) or HBx (C) culture medium. BrdUrd was visualized by immunostaining with
anti-BrdUrd antibodies.
Tralhao et al. PNAS  May 14, 2002  vol. 99  no. 10  6995
M
ED
IC
A
L
SC
IE
N
CE
S
detected at all stages of HBV infection and there is also evidence
for a cellular immune response to this viral protein (72). It should,
however, be noted that our results were obtained in the context of
only a moderate accumulation of HBx, which may rather suggest the
role of an inhibitory molecule whose expression would be triggered
by HBx. Also of note, we failed to abrogate the inhibitory effect of
HBx-conditioned medium by using an anti-Myc antibody to deplete
Myc-tagged HBx potentially present in HBx-conditioned medium
(data not shown).
A large number of studies on experimental liver carcinogenesis
in mice and rats have established the importance for achieving
efficient tumor induction of combining the administration of a
genotoxic compound with the inhibition of normal liver cell growth,
thus triggering the clonal expansion of cells able to resist this
inhibitory signal (73–76). Our findings lead us to propose that a viral
protein implicated in human carcinogenesis, namely HBx, may in
fact act by combining intracellular and paracrine effects, and
inhibiting the proliferation of both infected and uninfected liver
cells in the context of liver regeneration. This dual property would
have a selective effect, promoting the expansion of cells resistant to
the inhibitory effect of HBx. Depending on the experimental
conditions, HBx has also been reported to stimulate cellular DNA
synthesis and inhibit apoptosis. Moreover, we have demonstrated
the biological impact of the HBx mutations observed in HCC tumor
cells that abrogate the proapoptotic effects of HBx and, possibly,
favor cell transformation (9). It is therefore plausible that, at later
stages during the course of HCC development, modifications of
HBx intracellular expression andor HBx mutations within infected
cells, as well as changes to the differentiation status of liver cells (8),
may favor the expansion of HBx-expressing cells. Although these
observations were made in the specific context of liver regeneration
triggered by partial hepatectomy, they may represent an important
mechanism of HBV-dependent liver carcinogenesis in the context
of chronic hepatitis and the associated stimulation of liver cell
proliferation. Finally, our results suggest that this combination of
transgenic- and cell transplantation-based studies may constitute an
important experimental approach in the future, for example, in the
context of studies aiming to evaluate in vivo the importance of
natural HBx mutants (9).
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